Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|May 9, 2012
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaJürgen C Becker, Mads H Andersen, Valeska Hofmeister-Müller, et al.Molecular Medicine (Cambridge, Mass.)|December 28, 2012
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccinationHeike Pohla, Alexander Buchner, Birgit Stadlbauer, et al.Frontiers in Computational Neuroscience|August 12, 2022
Single channel approach for filtering electroencephalographic signals strongly contaminated with facial electromyographyCarlos Magno Medeiros Queiroz, Gustavo Moreira da Silva, Steffen Walter, et al.NPJ Digital Medicine|July 29, 2026
Perceptions of simulated artificial intelligence in medical consultations: associations with stress, memory, and perceived credibilityCarlotta J Mayer, Tristan L Swysen, Tobias R Kurz, et al.Brain : a Journal of Neurology|March 16, 2012
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapyValérie Dutoit, Christel Herold-Mende, Norbert Hilf, et al.Cancer Immunology, Immunotherapy : CII|August 20, 2014
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer stainingLindsey Chudley, Katy J McCann, Adam Coleman, et al.Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.Cancer Immunology Research|April 30, 2014
Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunityKaroline Laske, Yuriy V Shebzukhov, Ludger Grosse-Hovest, et al.Immunological Reviews|October 14, 2017
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillanceNorma Bloy, Pauline Garcia, Céline M Laumont, et al.Pageof 8